Inactive Instrument
Antibe Therapeutics Inc. Stock
Stocks
ATE
CA0370255097
Biotechnology & Medical Research
OTC Markets Traded| 04/07/24 | Antibe Therapeutics : NOTICE TO CLAIMANTS OF ANTIBE THERAPEUTICS INC. (“ANTIBE”) | PU |
| 24/04/24 | Antibe Announces Appointment of Receiver | BU |
| 22/04/24 | ANTIBE PROVIDES UPDATE ON CCAA PROCEEDINGS | AQ |
| 19/04/24 | Antibe Provides Update on CCAA Proceedings | BU |
| 17/04/24 | Antibe Announces TSX Delisting Review | BU |
| Manager | Title | Age | Since |
|---|---|---|---|
Alain Wilson
DFI | Director of Finance/CFO | - | 01/12/2015 |
David Vaughan
CTO | Chief Tech/Sci/R&D Officer | 76 | - |
| Investor Relations Contact | 50 | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 08/03/24 | Option | Chief Technology Officer | 16,666 | 0.0317% | ||
| 08/03/24 | Option | Chief Technology Officer | 9,000 | 0.0171% | ||
| 08/03/24 | Option | Chief Executive Officer | 35,000 | 0.0665% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | +59.46% | - | - | 11.47M | |
| -1.79% | -2.27% | +43.23% | +88.96% | 67.98B | |
| -2.06% | -0.18% | +39.67% | +86.44% | 64.94B | |
| -0.31% | +6.54% | -12.96% | +378.92% | 27.58B | |
| +0.86% | +1.65% | -7.74% | -14.95% | 26.06B | |
| -3.00% | -2.90% | +33.13% | +12.54% | 25.74B | |
| -1.46% | +0.42% | +23.61% | -18.61% | 20.09B | |
| -2.96% | -15.21% | +216.20% | +368.10% | 17.16B | |
| -1.49% | -4.88% | -6.60% | +531.89% | 14.92B | |
| -0.20% | +8.37% | +55.78% | +164.98% | 14.62B | |
| Average | -1.24% | +0.26% | +42.70% | +177.58% | 31.01B | |
| Weighted average by Cap. | -1.52% | +0.18% | +38.37% | +137.35% |
Employees
11
